HMA: Procedural Advice on Repeat-Use.

This document describes the procedure to be adopted for “Repeat Use”. ...

HMA: Recommendation for Marketing Authorisation Holders on the Pharmacovigilance System and Risk Management Plan in the Mutual Recognition and Decentralised Procedures.

This CMDh guidance document aims to provide specific guidance for RMS and CMS on the submission of data related to Pharmacovigilance systems, the necessity for submission of Risk Management Plans ...

GMP: Revised EU Guideline on Good Distribution Practice with major Changes

The guideline was revised to take into account advancements of practices for an appropriate storage and distribution of medicinal products in the European Union. Moreover, it should take into ...

EMA: Risk Based Quality Management in Clinical Trials.

The purpose of this reflection paper is to facilitate the development of a more systematic, prioritised, risk-based approach to quality management of clinical trials, to support the principles of ...

GMP: FDA proposes Changes in Sterility Testing of Biological Products.

The proposed rule is intended to provide manufacturers of biological products with greater flexibility and to encourage the use of the most appropriate and state-of-the-art test methods for ...

EMA: New EMA Draft Guideline on Stability Data regarding Applications for Variations to a Marketing Authorisation.

This guideline addresses the requirements in terms of stability testing data which drug manufacturers have to provide when applying variations to a marketing authorisation. Due to the extensive ...

FDA: PET Drugs — Current Good Manufacturing Practice (CGMP)

This guidance is intended to help small businesses better understand and comply with the regulations issued by FDA concerning current good manufacturing practice (CGMP) for positron emission ...

GMP: New FDA Draft Guidance regarding Design Development of Medical Devices.

The goal of this guidance is to assist the medical devices industry in performing appropriate human factors testing on medical devices in order to reduce use error and injuries. The FDA hopes that ...

EMA: Concept paper on the revision of the guideline on nonclinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins

The Guideline on Similar Medicinal Products containing Low-Molecular-Weight Heparins (LMWH) lays down the non-clinical and clinical requirements for the development of LMWH claimed to be similar ...

EMA: Concept paper on the revision of the guideline on nonclinical and clinical development of similar biological medicinal products containing recombinant human insulin

The current Guidance on Similar Medicinal Products containing Recombinant Human Insulin provides recommendations for the development of recombinant soluble (short-acting) human insulin claimed to ...

kapitał ludzki

fundusz społeczny

Narodowe Centrum Badań i Rozwoju

innowacyjna gospodarka

rozwój regionalny